Breaking News on Contract Research, Manufacturing & Clinical Trials

Top Headlines

Private equity investments scare pharma clients, says CRO

Pharmaceutical clients view contract research organisations (CROs) with private equity investments as unstable and more focused on financial growth than their operations, according to Italian CRO Cromsource.

Related news

News in brief

AMRI says its long-term outlook remains positive with continued demand for its contract research services despite plans to shutter a Discovery and Development Services (DDS) facility.

Merck Millipore appoints a new CEO, senior changes at Quintiles' Novella, and more.

Consultancy and drug developer Certara has acquired specialty contract research organization (CRO) Synchrogenix Information Strategies, which offers regulatory writing and related services to biopharma and medical device companies worldwide. 

US health insurer Independence Blue Cross (IBC) has selected LabCorp to be its preferred provider for outpatient and specialty lab services under a new eight year deal.

Global Industry News

Discovery of tampered vials leads to Roche cancer drug recall from in-PharmaTechnologist.com

Roche has recalled nine batches of breast cancer drug Herceptin after tampered vials were discovered in the UK, Finland and Germany.

Amine goldmine: BASF commits to new plant citing growing demand from in-PharmaTechnologist.com

The amines market will grow 5% over the next decade according to BASF, which cited rising drugmaker demand as a key driver for its investment in a new German plant.

Thermo Fisher: new pumps compatible with all bioprocessing techs from BioPharma-Reporter.com

Thermo Fisher has launched a pump technology designed for applications across the bioprocessing production line and usable with "all" bioprocessing tech.

Catalent to provide cell lines for at least three Hisun biosimilars in China from BioPharma-Reporter.com

Catalent will provide Hisun Pharmaceuticals with cell lines to help it develop infliximab, adalimumab and alemtuzumab biosimilars for the Chinese market.

NeoStem adds facility with $124M California Stem Cell acquisition from BioPharma-Reporter.com

Cell therapy developer NeoStem has agreed to acquire California Stem Cell in a deal worth up to $124M, and includes CSC’s manufacturing facility in Irvine, CA.

Spotlight

Biotech and pipeline refills add to preclinical turnaround, say analysts

Biotech and pipeline refills add to preclinical turnaround, say analysts

Demand from biotech firms and Big Pharma’s need to refill its pipeline is driving the preclinical services...

Drugmakers start your engines: GSK's Formula One discovery formula

Drugmakers start your engines: GSK's Formula One discovery formula

GSK has asked Formula One team Mclaren to help it discover drugs, arguing that Big Data expertise...

AmerisourceBergen to launch $100m distribution JV in Brazil

AmerisourceBergen to launch $100m distribution JV in Brazil

AmerisourceBergen (ABC) plans to buy a minority stake in a Brazilian drug wholesaler and outlined plans for...

AMRI to acquire CDMO Cedarburg for $41M

AMRI to acquire CDMO Cedarburg for $41M

AMRI will acquire Cedarburg Pharmaceuticals for $38.2m (€27.7) in cash, plus $2.8m of assumed liabilities, to expand...

Evotec buys academic asset management specialist

Evotec buys academic asset management specialist

Evotec AG has bought an asset management company that specialises in bringing academic discovery and development innovations...

Key Industry Events

Interphex 2014

New York, NY 10001 / Conference and exhibition

Read more

Access all events listing